|Slideshows|December 16, 2019

8 Tips to Prevent Physician Burnout and Enhance Well-Being in 2020

We may have strong (psychological) bones, but they are still susceptible to stress fractures. Face the new year armed with these guidelines on combatting symptoms of burnout, written by an expert in the field.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Looking Back: Key Insights from November 2025

ByJessica Walters

November 28th 2025

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

ByJessica Walters

November 24th 2025

transcranial magnetic stimulation depression treatment

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

ByRachel Rohaidy, MD

November 24th 2025

Addressing Treatment-Resistant Depression: Opportunities and Challenges

ByMichael Asbach, DMSc, PA-C, Psych-CAQ,Erin Crown, MHS, PA-C, Psych-CAQ,Kristin M. Clemens, PMHNP-BC, APRN, DNP,Susan R. Chapman, MSN, APRN, FNP-BC, PMHNP-BC

November 21st 2025

transcranial magnetic stimulation at-home depression treatment

At-Home Brain Stimulation Technologies for Treatment of Depression

ByKultar Singh Garcha, MD,Jessica Walters

November 19th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

8 Tips to Prevent Physician Burnout and Enhance Well-Being in 2020

Newsletter

Related Content

Looking Back: Key Insights from November 2025

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

Addressing Treatment-Resistant Depression: Opportunities and Challenges

At-Home Brain Stimulation Technologies for Treatment of Depression

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

November in Review: Updates on the Psychiatric Treatment Pipeline

Looking Back: Key Insights from November 2025

New Drug Application Submitted for Centanafidine for Treatment of ADHD